WIN-Partners Co., Ltd.

Tokyo Stock Exchange 3183.T

WIN-Partners Co., Ltd. EBITDA for the year ending March 31, 2024: USD 19.27 M

WIN-Partners Co., Ltd. EBITDA is USD 19.27 M for the year ending March 31, 2024, a -17.73% change year over year. EBITDA means earnings before interest, taxes, depreciation, and amortization, which measures a company's operating performance by excluding non-operating expenses.

WIN-Partners Co., Ltd. EBITDA for the year ending March 31, 2023 was USD 23.42 M, a 1.25% change year over year.
WIN-Partners Co., Ltd. EBITDA for the year ending March 31, 2022 was USD 23.13 M, a 4.57% change year over year.
WIN-Partners Co., Ltd. EBITDA for the year ending March 31, 2021 was USD 22.12 M, a -16.42% change year over year.
WIN-Partners Co., Ltd. EBITDA for the year ending March 31, 2020 was USD 26.46 M, a -16.14% change year over year.

Key data

Date	EBITDA	Net Income	EPS (Diluted)	Shares (Diluted, Weighted)

Tokyo Stock Exchange: 3183.T

WIN-Partners Co., Ltd.

CEO	Mr. Hideumi Akizawa
IPO Date	Sept. 16, 2002
Location	Japan
Headquarters	Kyobashi Edogrand
Employees	629
Sector	Healthcare
Industries Medical Instruments 3D Printing Biotechnology Hardware & Electronics

Description

WIN-Partners Co., Ltd., through its subsidiaries, distributes medical devices to medical institutions primarily in Japan. The company offers percutaneous transluminal coronary angioplasty balloon catheters, drug-eluting stents, and intravascular ultrasound catheters; pacemakers, implantable cardioverter defibrillators, cardiac resynchronization therapy defibrillators, and ablation catheters; and stent grafts, transcatheter heart valves, and mechanical heart valves. It also provides peripheral vascular stents, carotid artery stents, and embolic coils; and insulin pumps, as well as continuous glucose monitoring and magnetic resonance imaging equipment. The company was founded in 1973 and is headquartered in Tokyo, Japan.

Key trends

Past 5 years